|
Oncolytics Biotech® Inc. is conducting clinical trials in the U.S. and the U.K. with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes eight Phase I/II or Phase II human trials examining REOLYSIN® alone or in combination with chemotherapy.
This clinical program is designed to identify targets for late-stage registration trials with REOLYSIN®, the first of which is planned to be a Phase III combination REOLYSIN® and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers.
|
